1. Home
  2. AZTR vs SVRE Comparison

AZTR vs SVRE Comparison

Compare AZTR & SVRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Azitra Inc

AZTR

Azitra Inc

HOLD

Current Price

$0.23

Market Cap

3.5M

Sector

Health Care

ML Signal

HOLD

Logo SaverOne 2014 Ltd.

SVRE

SaverOne 2014 Ltd.

HOLD

Current Price

$4.40

Market Cap

3.7M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
AZTR
SVRE
Founded
2014
2014
Country
United States
Israel
Employees
N/A
35
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.5M
3.7M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
AZTR
SVRE
Price
$0.23
$4.40
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$4.00
N/A
AVG Volume (30 Days)
453.5K
26.0K
Earning Date
05-08-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
5.06
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$1,793.31
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.10
$0.55
52 Week High
$1.40
$6.30

Technical Indicators

Market Signals
Indicator
AZTR
SVRE
Relative Strength Index (RSI) 51.63 46.11
Support Level $0.21 $3.02
Resistance Level $0.23 $4.92
Average True Range (ATR) 0.02 0.45
MACD 0.00 -0.08
Stochastic Oscillator 74.80 8.51

Price Performance

Historical Comparison
AZTR
SVRE

About AZTR Azitra Inc

Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.

About SVRE SaverOne 2014 Ltd.

Saverone 2014 Ltd is engaged in the design, development, and commercialization of transportation and safety solutions, designed to prevent car accidents based on its patented technology of detecting, analyzing, and locating cellular phone radio frequency, or RF signals. The company is developing two product lines: the first is an In-Cabin Driver Distraction Prevention Solution (known as SaverOne system), or DDPS; and the second is an Advanced Driver-Assistance System, or ADAS, product that detects vulnerable road users, or VRUs, and provides a warning to the vehicle regarding potential collision. Geographically, Saverone generates maximum revenue from Europe and the rest from Israel.

Share on Social Networks: